The meriT-V Study

Study Highlights

- Principal Investigator: Dr. Alexandre Abizaid

- The meriT-V is a prospective, multicentre, randomized, open-label, non-inferiority trial of the BioMime sirolimus-eluting coronary stent system (SES) as compared to the XIENCE family of everolimus-eluting coronary stents (EES) in the treatment of patients with de novo native coronary artery lesions

- Two-year clinical follow-up including angiographic analysis at 9-month

- BioMime SES was non-inferior to XIENCE EES for the primary endpoint of in-stent late lumen loss

Clinical outcomes of BioMime SES at 9 months:
- 2.98% MACE
- 0% cardiac death
- 0% ST
- 0.15 mm In-stent LLL
### Study Design

A prospective, multicentre, randomized, open-label, active-controlled, non-inferiority trial

<table>
<thead>
<tr>
<th>256 patients were enrolled and randomly assigned (2:1) to BioMime SES or XIENCE EES between November 2014 and December 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 investigational sites in Europe (12 sites, including the Netherlands, Belgium, UK, Spain, Latvia, FYR of Macedonia, Czech Republic, and Poland) and Brazil (3 sites)</td>
</tr>
<tr>
<td>Clinical follow-up at 30-day, 5-month, 9-month, 12-month and 24-month post-procedure</td>
</tr>
<tr>
<td>Angiographic follow-up at 9-month</td>
</tr>
<tr>
<td>Analysed by Cardiovascular Research Centre, Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>
Study Results

Figure 1: Late Lumen Loss at 9-month Follow-up

Figure 2: Cumulative event curve of MACE
Figure 3: Cumulative event curve of MI

Figure 4: Cumulative event curve of ID-TV-R
References